Argireline vs IGF-1 LR3
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
ArgirelineAnabolic & IGF
IGF-1 LR3- Summary
- Argireline is the most widely researched topical 'Botox-alternative' cosmetic peptide, an acetylated hexapeptide that inhibits neuromuscular transmission to relax facial muscles and reduce dynamic wrinkle depth by 17–27% in clinical studies.
- IGF-1 LR3 is a synthetic analog of Insulin-like Growth Factor-1 with an extended half-life. It is one of the most potent anabolic peptides available, directly stimulating muscle cell hyperplasia and hypertrophy, and is the downstream mediator of many of GH's anabolic effects.
- Half-Life
- N/A — topical application; effect duration linked to formulation contact time
- 20–30 hours
- Admin Route
- Topical
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 5–10% concentration
- 40–80 mcg
- Frequency
- Twice daily
- Once daily or split twice daily
- Key Benefits
- Reduces depth of dynamic expression wrinkles 17–27%
- Non-invasive topical Botox alternative
- Smooths forehead, eye area, nasolabial fold lines
- Widely studied — published clinical efficacy data
- Synergistic with SNAP-8 for enhanced effect
- Reduces fine lines around eyes (crow's feet)
- Improves skin smoothness and texture
- Well tolerated across all skin types
- Direct muscle hypertrophy via IGF-1R stimulation
- Muscle hyperplasia (new fiber formation) — unique among peptides
- Rapid gains in lean muscle mass
- Accelerated recovery from training and injury
- Increased nutrient uptake by muscle cells
- Fat oxidation enhancement
- Bone density improvement
- Cartilage and connective tissue repair
- Side Effects
- Generally very well tolerated
- At >10%: temporary eyelid/brow ptosis (drooping)
- Rare: mild redness in sensitive skin
- No systemic absorption at cosmetic doses
- Hypoglycemia (significant risk — insulin-like activity)
- Acromegaly-like effects with excessive long-term use
- Jaw and hand swelling
- Organ hypertrophy with extreme doses
- +2 more
- Stacks With
- —
- —